Cargando…
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial
Tumor mutational burden (TMB) in circulating tumor DNA (ctDNA) has shown promise in predicting benefit from PD-L1/PD-1 inhibitors in retrospective studies. Aiming to assess blood TMB (bTMB) prospectively, we conducted B-F1RST (NCT02848651), an open-label, phase 2 trial that evaluated bTMB as a predi...
Autores principales: | Kim, Edward S., Velcheti, Vamsidhar, Mekhail, Tarek, Yun, Cindy, Shagan, Sarah M., Hu, Sylvia, Chae, Young Kwang, Leal, Ticiana A., Dowell, Jonathan E., Tsai, Michaela L., Dakhil, Christopher S. R., Stella, Philip, Jin, Yanling, Shames, David S., Schleifman, Erica, Fabrizio, David A., Phan, See, Socinski, Mark A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117143/ https://www.ncbi.nlm.nih.gov/pubmed/35422531 http://dx.doi.org/10.1038/s41591-022-01754-x |
Ejemplares similares
-
Regulatory role of the RstB‐RstA system in adhesion, biofilm production, motility, and hemolysis
por: Huang, Lixing, et al.
Publicado: (2018) -
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial
por: Peters, Solange, et al.
Publicado: (2022) -
The ferumoxytol in renal insufficiency study (FiRST)
por: Vemulapalli, Sreekanth, et al.
Publicado: (2013) -
Muon performance and related ATLAS fi rst physics
por: Moreno Llacer, M
Publicado: (2010) -
RST Digital Algorithm for Controlling the LHC Magnet Current
por: Bordry, Frederick, et al.
Publicado: (1998)